Feature | March 24, 2010| Dave Fornell

Endeavor Stent Long-Term Data Shows Consistent Safety, Efficacy

Danish study disputes findings, favors the Cypher in comparison.

While short term trial outcomes of the Endeavor Zotarolimus-Eluting Coronary Stent favored the Cypher Sirolimus-Eluting Coronary Stent, long-term results favored Endeavor.

Five-year results from the ENDEAVOR-III trial.

Final five-year results from the ENDEAVOR III trial, comparing the Endeavor Zotarolimus-Eluting Coronary Stent to the Cypher Sirolimus-Eluting Coronary Stent, showed Endeavor had lower long-term rates of adverse events, cardiovascular death and heart attacks. The results were released last week during the American College of Cardiology’s 59th Scientific Session.

“I think physicians using the Endeavor will feel even more bolstered and reassured about using Endeavor,” said David Kandzari, M.D., director of interventional cardiology research at Scripps Clinic in La Jolla, Calif., and co-principal investigator ENDEAVOR III and ENDEAVOR IV clinical studies. “Over the long term the hallmark of the Endeavor stent is safety.”

Major adverse cardiac events (MACE) were 13.6 percent for Endeavor, verses 21.8 percent for Cypher. Rates for cardiac death/myocardial infarction (CD/MI) were Endeavor 1.3 vs. 6.5 percent for Cypher. Definite and probable stent thrombosis (ST) rates were Endeavor 1 vs. 3.7 percent for Cypher.

Target Lesion Revascularization Rates Differ

Cypher did fair better than Endeavor in target lesion revascularization (TLR) rates – Endeavor 8 vs. 6.5 percent for Cypher.

“Most of the target lesion revascularizations are occurring in the first year,” Dr. Kandzari said. “When we look at patients treated with Endeavor after one year, we see very low rates of target lesion revascularization. It does support the notion that while TLR is higher earlier on, that difference starts to erode over time.”

The TLR rates between years two through five showed late catch-up in TLR with Cypher, with an increase of 86 percent compared to 21 percent with the Endeavor. Additionally, MACE increased in the Cypher patients by 173 percent compared to 74 percent in the Endeavor patients.

While the results observed increase in late clinical events with the Cypher, the trial was not designed or powered to detect differences in clinical events. The randomized, controlled trial had a primary angiographic endpoint of late lumen loss at eight months. “Despite differences early on with early late loss, it did not translate into late loss,” Dr. Kandzari said.

The definitive study comparing the Endeavor to Cypher is PROTECT, which includes 8,800 patients. It is designed to evaluate whether the Endeavor protects against late stent thrombosis and results in fewer deaths and heart attacks at three years. Enrollment in the PROTECT study was completed in December 2008.

Pooled Endeavor Results

Pooled results from several clinical trials for the Endeavor also show very good longer-term results, including a low rate of late repeat revascularization and few late stent thrombotic events. Five-year findings from the comprehensive ENDEAVOR clinical trial program were also released at ACC 2010.

The E-Pooled analysis includes clinical data on more than 2,100 Endeavor patients from six clinical trials. These include five-year data from the ENDEAVOR I (E-I), ENDEAVOR II (E-II), E-II Continued Access (CA), and ENDEAVOR III (E-III) clinical studies, and three-year data from the ENDEAVOR IV (E-IV) and ENDEAVOR Pharmacokinetics (E-PK) clinical studies. The results were consistent across these studies.

“The consistency of results across these well conducted clinical trials is remarkable,” Dr. Kandzari said. “The Endeavor stent has demonstrated a very compelling safety and efficacy profile wherein there is a very low likelihood that patients treated with the Endeavor stent will experience late stent clotting or the need for a repeat procedure beyond the first year of follow up.”

The E-Pooled analysis includes patients who were treated with the Endeavor DES (in E-I, E-PK, E-II, E-II CA, E-III and E-IV trials) and uses the Medtronic Driver bare-metal stent (BMS) control arm of E-II as a comparator.

Of particular relevance are the longitudinal safety results, including the low rates of cardiac death/myocardial infarction and probable stent thrombosis, which are achieved against a background of only 39 percent and 8 percent of Endeavor patients being maintained on dual-anti-platelet therapy at one year and five years of follow-up, respectively.

Study Questions Endeavor’s Efficacy

Despite these positive findings, they are disputed by the data from the Danish SORT OUT III trial comparing Endeavor to Cypher. The latest results from that trial were also presented at ACC 2010. In that study, data shows patients treated with Endeavor had more MACE events at 18 months than those treated with Cypher.

The main risk reduction that favored Cypher was in TLR (Endeavor 6 vs. 2 percent for Cypher). Data also showed lower rates of myocardial infarction (MI was Endeavor 2 vs. 1 percent for Cypher). Dr. Klaus Rasmussen from Aarhus University Hospital where the study was conducted said the Endeavor stent is no longer used at the hospital because of the findings.

Medtronic, which manufactures Endeavor, said the SORT-OUT III study used unconventional design and analytical methods, which are biased against Endeavor. Unlike the Endeavor clinical trials that used randomized controlled trials with rigorous patient follow-up, SORT-OUT III is dependent on patient records from a national database, the company said. The investigators themselves – not an independent clinical events committee – also determined and verified stent thrombosis, TLR, MI and restenosis. The study was also criticized for being positioned as a real-world study, but nearly 60 percent (3,344) of eligible patients were excluded in the analysis. Differences in patient adherence to dual anti-platelet therapy regimens were also not reported, despite the potential affect on safety outcomes.

Dr. Kandzari said Endeavor makes up about a third of the U.S. DES market.

Related Content

St. Jude Medical, ADO II AS trial, congenital heart disease, PDA, Amplatzer Duct Occluder II AS
News | Congenital Heart| October 19, 2016
St. Jude Medical Inc. announced the launch of the ADO II AS (AMPLATZER Duct Occluder II Additional Sizes) pediatric...
Lantheus, flurpiridaz F-18, myocardial perfusion imaging, MPI, cardiac stress testing, ASNC 2016
News | Radiopharmaceuticals and Tracers| October 17, 2016
Lantheus Holdings Inc. announced in late September that sub-analysis data from the first Phase 3 study of flurpiridaz F...
Medtronic, FIRE AND ICE trial, Arctic Front, cryoballoon catheter ablation, radiofrequency RF ablation, study results, Asia Pacific Heart Rhythm Society Scientific Sessions
News | Ablation Systems| October 17, 2016
Medtronic plc last week unveiled new health economic analysis data from the FIRE AND ICE trial that favor cryoballoon...
transcarotid artery revascularization, TCAR Surveillance Project, Society for Vascular Surgery Patient Safety Organization, SVS PSO,
News | Stents Carotid| October 13, 2016
A surveillance project to evaluate the safety and effectiveness of transcarotid artery revascularization (TCAR) in...
Shockwave lithoplasty system, VIVA 16, Vascular Interventioanl Advances, VIA Physicians, late-breaking endovascular clinical trial results
News | Cath Lab| October 12, 2016
VIVA (Vascular Interventional Advances) Physicians announced a number of highly anticipated late-breaking clinical...
ZipLine Medical, Zip Surgical Skin Closure, cath lab time savings, PACE study
News | EP Lab| October 10, 2016
October 10, 2016 — ZipLine Medical Inc.
Mercator MedSystems, Bullfrog Micro-Infusion Device, DANCE trial, VIVA 2016, 13-month results
News | Peripheral Arterial Disease (PAD)| October 07, 2016
Mercator MedSystems recently announced that 13-month data from the DANCE trial was presented during a late-breaking...
Keystone Heart, TriGuard Embolic Protection Device, Neuro-TAVR study, brain lesions, American Journal of Cardiology
News | Heart Valve Technology| October 03, 2016
Keystone Heart Ltd. announced data recently published in the American Journal of Cardiology demonstrating new brain...
TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
News | Pharmaceuticals| September 26, 2016
Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack...
Overlay Init